Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

Epigenome- and Transcriptome-wide Changes in Muscle Stem Cells from Low Birth Weight Men.

Broholm C, Ribel-Madsen R, Hjort L, Olsson AH, Ahlers JMD, Hansen NS, Schrölkamp M, Gillberg L, Perfilyev A, Volkov P, Ling C, Jørgensen SW, Mortensen B, Hingst J, Wojtaszewski J, Scheele C, Brøns C, Pedersen BK, Vaag A.

Endocr Res. 2019 Sep 30:1-14. doi: 10.1080/07435800.2019.1669160. [Epub ahead of print]

PMID:
31566019
2.

Stability Effect of Quinary Interactions Reversed by Single Point Mutations.

Gnutt D, Timr S, Ahlers J, König B, Manderfeld E, Heyden M, Sterpone F, Ebbinghaus S.

J Am Chem Soc. 2019 Mar 20;141(11):4660-4669. doi: 10.1021/jacs.8b13025. Epub 2019 Feb 21.

PMID:
30740972
3.
4.

Prognostic value of the new high sensitive cardiac troponin T assay (hs-cTnT) after coronary artery bypass grafting.

Mehdiani A, Akhyari P, Kamiya H, Ahlers J, Godehardt E, Albert A, Boeken U, Lichtenberg A.

Acta Cardiol. 2017 Jun;72(3):276-283. doi: 10.1080/00015385.2017.1304693. Epub 2017 Mar 21.

PMID:
28636504
5.

The German postgraduate degree program in ecotoxicology (SETAC GLB and GDCh): a success story.

Ebke KP, Ahlers J, Braunbeck T, Oehlmann J, Ratte T, Schäfer RB, Eisenträger A, Schäffer A.

Environ Sci Eur. 2016;28(1):19. Epub 2016 Jun 23.

6.

Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.

Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, Smith MZ, Spelman T, McMahon J, Velayudham P, Brown G, Roney J, Watson J, Prince MH, Hoy JF, Chomont N, Fromentin R, Procopio FA, Zeidan J, Palmer S, Odevall L, Johnstone RW, Martin BP, Sinclair E, Deeks SG, Hazuda DJ, Cameron PU, Sékaly RP, Lewin SR.

PLoS Pathog. 2014 Nov 13;10(10):e1004473. doi: 10.1371/journal.ppat.1004473. eCollection 2014 Oct.

7.

Pourfour du petit syndrome after supraclavicular catheter discontinuation.

Van Demark KM, Nicholas TA, Ahlers JM, Adams JJ, Burton BR, Ward DR, Hofmann SC.

Reg Anesth Pain Med. 2014 Sep-Oct;39(5):440. doi: 10.1097/AAP.0000000000000123. No abstract available.

PMID:
25140511
8.

Role of Blimp-1 in programing Th effector cells into IL-10 producers.

Neumann C, Heinrich F, Neumann K, Junghans V, Mashreghi MF, Ahlers J, Janke M, Rudolph C, Mockel-Tenbrinck N, Kühl AA, Heimesaat MM, Esser C, Im SH, Radbruch A, Rutz S, Scheffold A.

J Exp Med. 2014 Aug 25;211(9):1807-19. doi: 10.1084/jem.20131548. Epub 2014 Jul 29.

10.

Therapy response correlates with ALDH activity in ALDH low-positive childhood acute lymphoblastic leukemias.

Ahlers J, Witte KE, Schwarze CP, Lang P, Handgretinger R, Ebinger M.

Pediatr Hematol Oncol. 2014 May;31(4):303-10. doi: 10.3109/08880018.2013.859189. Epub 2013 Dec 5.

PMID:
24308780
11.

Programmed death-1 is a marker for abnormal distribution of naive/memory T cell subsets in HIV-1 infection.

Breton G, Chomont N, Takata H, Fromentin R, Ahlers J, Filali-Mouhim A, Riou C, Boulassel MR, Routy JP, Yassine-Diab B, Sékaly RP.

J Immunol. 2013 Sep 1;191(5):2194-204. doi: 10.4049/jimmunol.1200646. Epub 2013 Aug 5.

12.

The immunological synapse: the gateway to the HIV reservoir.

Kulpa DA, Brehm JH, Fromentin R, Cooper A, Cooper C, Ahlers J, Chomont N, Sékaly RP.

Immunol Rev. 2013 Jul;254(1):305-25. doi: 10.1111/imr.12080. Review.

13.

PD-1 coinhibitory signals: the link between pathogenesis and protection.

Kulpa DA, Lawani M, Cooper A, Peretz Y, Ahlers J, Sékaly RP.

Semin Immunol. 2013 Oct 31;25(3):219-27. doi: 10.1016/j.smim.2013.02.002. Epub 2013 Mar 31. Review.

14.

Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs.

Katlama C, Deeks SG, Autran B, Martinez-Picado J, van Lunzen J, Rouzioux C, Miller M, Vella S, Schmitz JE, Ahlers J, Richman DD, Sekaly RP.

Lancet. 2013 Jun 15;381(9883):2109-17. doi: 10.1016/S0140-6736(13)60104-X. Epub 2013 Mar 29. Review.

15.

An open-ended plea for the development of a global database of HIV vaccine responses.

Wilkinson P, Filali-Mouhim A, Li S, Ahlers J, Schatzle J, Pulendran B, Sekaly RP, Cameron MJ.

Curr Opin HIV AIDS. 2012 Jan;7(1):10-6. doi: 10.1097/COH.0b013e32834e390a. Review.

17.

High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia.

Witte KE, Ahlers J, Schäfer I, André M, Kerst G, Scheel-Walter HG, Schwarze CP, Pfeiffer M, Lang P, Handgretinger R, Ebinger M.

Pediatr Hematol Oncol. 2011 Mar;28(2):91-9. doi: 10.3109/08880018.2010.528171. Epub 2011 Jan 8.

PMID:
21214408
18.

Mucosal immunity and HIV-1 infection: applications for mucosal AIDS vaccine development.

Belyakov IM, Ahlers JD.

Curr Top Microbiol Immunol. 2012;354:157-79. doi: 10.1007/82_2010_119. Review.

PMID:
21203884
19.

Molecular pathways regulating CD4(+) T cell differentiation, anergy and memory with implications for vaccines.

Ahlers JD, Belyakov IM.

Trends Mol Med. 2010 Oct;16(10):478-91. doi: 10.1016/j.molmed.2010.07.007. Epub 2010 Aug 24. Review.

PMID:
20739220
20.

New paradigms for generating effective CD8+ T cell responses against HIV-1/AIDS.

Ahlers JD, Belyakov IM.

Discov Med. 2010 Jun;9(49):528-37.

21.

High frequency of immature cells at diagnosis predicts high minimal residual disease level in childhood acute lymphoblastic leukemia.

Ebinger M, Witte KE, Ahlers J, Schäfer I, André M, Kerst G, Scheel-Walter HG, Lang P, Handgretinger R.

Leuk Res. 2010 Sep;34(9):1139-42. doi: 10.1016/j.leukres.2010.03.023. Epub 2010 Apr 7.

PMID:
20378168
22.

Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS.

Ahlers JD, Belyakov IM.

Trends Immunol. 2010 Mar;31(3):120-30. doi: 10.1016/j.it.2009.12.003. Epub 2010 Jan 19. Review.

PMID:
20089450
23.

What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?

Belyakov IM, Ahlers JD.

J Immunol. 2009 Dec 1;183(11):6883-92. doi: 10.4049/jimmunol.0901466. Review.

24.

Memories that last forever: strategies for optimizing vaccine T-cell memory.

Ahlers JD, Belyakov IM.

Blood. 2010 Mar 4;115(9):1678-89. doi: 10.1182/blood-2009-06-227546. Epub 2009 Nov 10. Review.

25.

Strategies for optimizing targeting and delivery of mucosal HIV vaccines.

Ahlers JD, Belyakov IM.

Eur J Immunol. 2009 Oct;39(10):2657-69. doi: 10.1002/eji.200939269. Review.

26.

Strategies for recruiting and targeting dendritic cells for optimizing HIV vaccines.

Ahlers JD, Belyakov IM.

Trends Mol Med. 2009 Jun;15(6):263-74. doi: 10.1016/j.molmed.2009.04.003. Epub 2009 May 30. Review.

PMID:
19487159
27.

Comment on "trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination".

Belyakov IM, Ahlers JD.

J Immunol. 2009 Feb 15;182(4):1779; author reply 1779-80. doi: 10.4049/jimmunol.0990002. No abstract available.

28.

[Treatment options for cartilage damage in the knee joint (II)].

Ahlers J.

Versicherungsmedizin. 2008 Dec 1;60(4):170-6. German. No abstract available.

PMID:
19119779
29.

The EU existing chemicals regulation: A suitable tool for environmental risk assessment and risk management?

Ahlers J.

Environ Sci Pollut Res Int. 1999;6(3):127-9. doi: 10.1007/BF02987609. No abstract available.

PMID:
19009382
30.

Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine.

Belyakov IM, Ahlers JD.

Trends Immunol. 2008 Nov;29(11):574-85. doi: 10.1016/j.it.2008.07.010. Review.

PMID:
18838298
31.

Integrated testing and intelligent assessment-new challenges under REACH.

Ahlers J, Stock F, Werschkun B.

Environ Sci Pollut Res Int. 2008 Oct;15(7):565-72. doi: 10.1007/s11356-008-0043-y. Epub 2008 Sep 26.

PMID:
18818964
32.

[Treatment options for cartilage damage in the knee joint].

Ahlers J.

Versicherungsmedizin. 2008 Sep 1;60(3):114-7. Review. German.

PMID:
18807341
33.

Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization.

Belyakov IM, Ahlers JD, Nabel GJ, Moss B, Berzofsky JA.

Virology. 2008 Nov 10;381(1):106-15. doi: 10.1016/j.virol.2008.08.019. Epub 2008 Sep 14.

34.

Role of alpha3 domain of class I MHC molecules in the activation of high- and low-avidity CD8+ CTLs.

Belyakov IM, Kozlowski S, Mage M, Ahlers JD, Boyd LF, Margulies DH, Berzofsky JA.

Int Immunol. 2007 Dec;19(12):1413-20. Epub 2007 Nov 1.

PMID:
17981793
35.

Acute to chronic ratios in aquatic toxicity--variation across trophic levels and relationship with chemical structure.

Ahlers J, Riedhammer C, Vogliano M, Ebert RU, Kühne R, Schüürmann G.

Environ Toxicol Chem. 2006 Nov;25(11):2937-45.

PMID:
17089717
36.

Progress on new vaccine strategies against chronic viral infections.

Berzofsky JA, Ahlers JD, Janik J, Morris J, Oh S, Terabe M, Belyakov IM.

J Clin Invest. 2004 Aug;114(4):450-62. Review.

37.

Mucosal AIDS vaccines: current status and future directions.

Belyakov IM, Ahlers JD, Berzofsky JA.

Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S65-73. Review.

PMID:
15285706
38.

Progress on new vaccine strategies for the immunotherapy and prevention of cancer.

Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC.

J Clin Invest. 2004 Jun;113(11):1515-25. Review.

39.

Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells.

Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA.

J Clin Invest. 2004 Apr;113(7):998-1007.

40.

Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.

Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, Wyatt LS, Snyder JT, Ahlers JD, Franchini G, Moss B, Berzofsky JA.

Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9458-63. Epub 2003 Jul 17.

42.

Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines.

Ahlers JD, Belyakov IM, Berzofsky JA.

Curr Mol Med. 2003 May;3(3):285-301. Review.

PMID:
12699364
43.

Selective induction of high avidity CTL by altering the balance of signals from APC.

Oh S, Hodge JW, Ahlers JD, Burke DS, Schlom J, Berzofsky JA.

J Immunol. 2003 Mar 1;170(5):2523-30.

44.

A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L.

Ahlers JD, Belyakov IM, Terabe M, Koka R, Donaldson DD, Thomas EK, Berzofsky JA.

Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13020-5. Epub 2002 Sep 13.

45.

Assessing CD4+ helper T-lymphocyte responses by lymphoproliferation.

Quakyi IA, Ahlers JD.

Methods Mol Med. 2002;72:369-83. No abstract available.

PMID:
12125133
46.

Strategies for designing and optimizing new generation vaccines.

Berzofsky JA, Ahlers JD, Belyakov IM.

Nat Rev Immunol. 2001 Dec;1(3):209-19. Review.

PMID:
11905830
47.

Activating CTL precursors to reveal CTL function without skewing the repertoire by in vitro expansion.

Belyakov IM, Wang J, Koka R, Ahlers JD, Snyder JT, Tse R, Cox J, Gibbs JS, Margulies DH, Berzofsky JA.

Eur J Immunol. 2001 Dec;31(12):3557-66.

48.
49.

Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques.

Belyakov IM, Hel Z, Kelsall B, Kuznetsov VA, Ahlers JD, Nacsa J, Watkins DI, Allen TM, Sette A, Altman J, Woodward R, Markham PD, Clements JD, Franchini G, Strober W, Berzofsky JA.

Nat Med. 2001 Dec;7(12):1320-6.

PMID:
11726972
50.

Supplemental Content

Loading ...
Support Center